| dbo:abstract
|
- Tiomolibdic acid (trade name Decuprate) is a chelating agent under investigation for the treatment of cancer and of Wilson's disease, a rare and potentially fatal disease in which the body cannot regulate copper. It is developed by Wilson Therapeutics and used in form of the salt bis-choline tetrathiomolybdate. Wilson's disease is an autosomal recessive genetic disorder that is manifested by serious hepatic, neurologic or psychiatric symptoms. The disease is fatal if left untreated. It is estimated that approximately 1 individual in every 30,000 worldwide has Wilson's disease, corresponding to approximately 15,000 individuals in the European Union and approximately 11,000 in the United States. Bis-choline tetrathiomolybdate has been evaluated in clinical trials in patients with various forms of cancer and has received orphan designation in the US and EU as a potential therapy against Wilson's disease. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 18424 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:casNumber
|
- 13818 (xsd:integer)
- 16330 (xsd:integer)
|
| dbp:chemspiderid
|
- 10619308 (xsd:integer)
- 21494208 (xsd:integer)
|
| dbp:drugbank
| |
| dbp:h
| |
| dbp:index2Label
| |
| dbp:mo
| |
| dbp:pubchem
| |
| dbp:s
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- IEGNLZVDENYZEJ-UHFFFAOYSA-L (en)
|
| dbp:synonyms
|
- Tetrathiomolybdic acid; choline salt: ATN-224, WTX101, ALXN1840 (en)
|
| dbp:tradename
| |
| dbp:unii
|
- 91 (xsd:integer)
- 206 (xsd:integer)
|
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Tiomolibdic acid (trade name Decuprate) is a chelating agent under investigation for the treatment of cancer and of Wilson's disease, a rare and potentially fatal disease in which the body cannot regulate copper. It is developed by Wilson Therapeutics and used in form of the salt bis-choline tetrathiomolybdate. Bis-choline tetrathiomolybdate has been evaluated in clinical trials in patients with various forms of cancer and has received orphan designation in the US and EU as a potential therapy against Wilson's disease. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
